Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 +0.51%84 EV-to-EBIT is 19.44 as of Sep. 21, 2026, which is 14% below its 10-year median of 22.64. GuruFocus rates ROCO:4114 with a GF Score™ of 84/100 and a GF Value™ of NT$34.27 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 682 Drug Manufacturers companies, Synmosa Biopharma ranks worse than 58.5% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Synmosa Biopharma's Enterprise Value for the quarter that ended in Jun. 2026 was NT$18,792 Mil.
Synmosa Biopharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$874 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synmosa Biopharma EV-to-EBIT Related Terms
Synmosa Biopharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Synmosa Biopharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's EV-to-EBIT falls into.
Synmosa Biopharma's current Enterprise Value is NT$16,982 Mil.
Synmosa Biopharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$874 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synmosa Biopharma (ROCO:4114) has a EV-to-EBIT of 19.44 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Synmosa Biopharma and its competitors. This is 14% below median its historical median of 22.64. According to the industry distribution chart, Synmosa Biopharma ranks #399 out of 682 companies in the Drug Manufacturers industry, placing it in the top 58.5%.
Is Synmosa Biopharma's EV-to-EBIT too high?
Synmosa Biopharma's current EV-to-EBIT of 19.44 is 14% below median its 10-year median of 22.64. The Drug Manufacturers industry median EV-to-EBIT is 16.03. Synmosa Biopharma's value of 19.44 is 21.3% above this industry median. Based on the distribution chart, Synmosa Biopharma ranks #399 out of 682 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Synmosa Biopharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #399 out of 682 companies for EV-to-EBIT. This places Synmosa Biopharma in the lower half of its industry. The industry median EV-to-EBIT is 16.03. Synmosa Biopharma's value of 19.44 is 21.3% above this benchmark. While the company's 10-year median is 22.64 vs. the industry median of 16.03, Synmosa Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.03, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synmosa Biopharma's current EV-to-EBIT of 19.44 is 21.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Synmosa Biopharma and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current EV-to-EBIT is 19.44, which is 14% below median its own 10-year median of 22.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$34.27, compared to a current price of NT$29.80 — trading 13% below its estimated fair value. The current EV-to-EBIT is 19.44, which is 14% below median its 10-year median of 22.64 and 21.3% above the Drug Manufacturers industry median of 16.03. Synmosa Biopharma's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current EV-to-EBIT is 19.44 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$29.80 is trading 13% below its estimated GF Value™ of NT$34.27.
GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:4114:
EV-to-EBIT: 19.44 (14% below median its 10-year median of 22.64)
GF Value™: NT$34.27 vs. price of NT$29.80 (13% below fair value)
Industry Position: 21.3% above the Drug Manufacturers median (#399 of 682)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
84GF Score
Get the complete analysis for ROCO:4114
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
